Studies have also reported that various oncogenes can facilitate CRC progression by enhancing SMAD2/3 activation or expression and activating the TGF-β pathway (Akhurst and Hata, 2012; Wu et al., 2021; Di et al., 2023). Here, SMAD2 is linked to colorectal carcinoma.